文献速递血管炎

托珠单抗治疗难治性大动脉炎的血管影像学分析

Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该事后分析纳入28例接受托珠单抗治疗的难治性大动脉炎患者,于基线和第48周行CT检查,由3名放射科医师独立评估22条动脉的壁厚度等指标至96周。结果显示86.7%的动脉壁厚度改善或稳定,约60%患者壁厚度无进展,少数出现扩张/动脉瘤或狭窄/闭塞进展;新发进展者激素难以减至0.1 mg/kg/日以下。

要点

  • 托珠单抗治疗后96周内约60%患者动脉壁厚度无进展。
  • 扩张/动脉瘤和狭窄/闭塞进展者比例较低。
  • 壁厚度新发进展者激素难以减至0.1 mg/kg/日以下。

核心结论

  • 约60%难治性大动脉炎患者接受托珠单抗治疗后96周内动脉壁厚度无进展。
  • 少数患者出现扩张/动脉瘤或狭窄/闭塞进展。
  • 壁厚度进展可能反映疾病更顽固,应定期影像监测并考虑加强激素或免疫抑制治疗。

研究设计与样本

  • III期随机对照试验的事后分析,纳入至少接受一剂托珠单抗且在基线和第48周行CT的28例患者。
  • 由3名未参与原试验的放射科医师独立评估每例患者22条动脉的影像学改变。

主要发现

  • 28例患者中,96周时86.7%的22条动脉壁厚度改善或稳定。
  • 壁厚度改善或稳定、部分进展、新发进展的患者比例分别为57.1%、10.7%、28.6%。
  • 扩张/动脉瘤改善或稳定的比例为92.9%,狭窄/闭塞改善或稳定的比例为85.7%。
  • 壁厚度新发进展的患者在第96周时激素剂量无法减至0.1 mg/kg/日以下。

关键数值与推荐

  • 主要终点为壁厚度较基线的变化,评估至托珠单抗启动后至少96周。
  • 同时评估扩张/动脉瘤、狭窄/闭塞和壁增强的变化。

临床怎么用

  • 对托珠单抗治疗后壁厚度进展的患者应定期影像监测。
  • 此类患者可考虑额外使用糖皮质激素或免疫抑制治疗以避免血管进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tocilizumab, an anti-IL-6 receptor antibody, was investigated in patients with refractory Takayasu arteritis (TAK) in a phase 3 randomized controlled trial. In this post hoc analysis, we investigated whether tocilizumab treatment inhibited the progression of vascular lesions caused by TAK in these patients. METHODS: Included patients received at least one dose of tocilizumab and underwent CT at baseline and at week 48 after tocilizumab initiation. Three radiologists not involved in the original trial independently evaluated the CT images. Twenty-two arteries from each patient were assessed for change from baseline in wall thickness (primary endpoint), dilatation/aneurysm, stenosis/occlusion or wall enhancement for at least 96 weeks after tocilizumab initiation. Patient-level assessments were also conducted. RESULTS: In 28 patients, 86.7% of 22 arteries had improved or stable wall thickness at week 96. Proportions of patients with improved or stable, partially progressed or newly progressed lesions were 57.1%, 10.7% and 28.6%, respectively, for wall thickness; proportions with improved or stable lesions were 92.9% for dilatation/aneurysm, and 85.7% for stenosis/occlusion. Patients with newly progressed lesions, reflecting more refractory disease, were prescribed glucocorticoids at dosages that could not be reduced below 0.1 mg/kg/day at week 96. CONCLUSIONS: Approximately 60% of patients with TAK did not experience progression in wall thickness within 96 weeks after initiation of tocilizumab treatment. Few patients experienced progressed dilatation/aneurysm, or stenosis/occlusion. Wall thickness progression likely resulted from refractory TAK. Patients who experience this should be monitored regularly by imaging, and additional glucocorticoid or immunosuppressive treatment should be considered to avoid vascular progression. TRIAL REGISTRATION: Japan Pharmaceutical Information Centre number, JapicCTI-142616.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Nakaoka Y, Yanagawa M, Hata A, et al. Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial. Rheumatology (Oxford). 2022. PMID: 34528074. doi:10.1093/rheumatology/keab684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。